ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig

ישראל - עברית - Ministry of Health

bayer israel ltd - regorafenib - טבליות מצופות פילם - regorafenib 40 mg - regorafenib - regorafenib - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and if kras wild-type, an anti-egfr therapy.for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (gist) who have been previously treated with imatinib mesylate and sunitinib malate

ישראל - עברית - Ministry of Health

amgen europe b.v. - panitumumab - תרכיז להכנת תמיסה לאינפוזיה - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type kras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type kras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.